Singapore's final drug registration guidance to address biosimilars and generics
This article was originally published in SRA
Executive Summary
Singapore's Health Sciences Authority has nearly finalised important changes to its guideline on the registration of medicinal products to incorporate, among other things, a new chapter on the registration of biosimilar products and a new fast-track procedure for evaluating generic drug applications1,2.